Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

Biochemical Pharmacology

Volumn 50, Issue 6, 1995, Pages 861-867

  Greene, Sharon ^a   Watanabe, Kiyotaka ^a   Braatz Trulson, Julie ^a   Lou, Lillian ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Brequinar; de novo pathway; dihydroortate dehydrogenase; leflunomide; pyrimidine nucleotide synthesis; uridine

Indexed keywords

ADENOSINE; BREQUINAR; CYTIDINE; DIHYDROOROTATE DEHYDROGENASE; DIHYDROOROTIC ACID; DRUG METABOLITE; GUANOSINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; PYRIMIDINE NUCLEOTIDE; RS 56338; TERIFLUNOMIDE; UBIQUINONE; UNCLASSIFIED DRUG; URIDINE; URIDINE PHOSPHATE;

ARTICLE; BIOSYNTHESIS; CELL GROWTH; CELL LINE; CONTROLLED STUDY; CYTOSTASIS; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOBLAST; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PYRIMIDINE METABOLISM;

ANILINE COMPOUNDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL DIVISION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; HYDROXYBUTYRATES; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; KINETICS; LYMPHOCYTES; MITOCHONDRIA; OXIDOREDUCTASES; UBIQUINONE; URIDINE MONOPHOSPHATE;

EID: 0029050136     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)00255-X     Document Type: Article

References (24)

1. Mycophenolate mofetil: A rationally designed irnmunosuppressive drug
2. Therapy of rheumatoid arthritis with mycophenolate mofetil
3. Mycophenolate mofetil: Molecular mechanisms of action
4. The Development of Brequinar as an Immunosuppressive Drug for Transplantation
5. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection
6. New Immunosuppressive Drugs: Mechanistic Insights and Potential Therapeutic Advances
7. Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis
8. Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide
9. Leflunomide, a novel immuno-suppressive agent. The mechanism of inhibition of T cell proliferation
10. Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers
11. Inhibition of the epidermal growth factor receptor tyro-sine kinase activity by leflunomide
12. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism
13. Leflunomide (HWA486): A novel immunorestoring drug
14. Pyrimidine nucleotide biosynthesis in animals: Genes, enzymes and regulation of UMP biosynthesis
15. Human GMP synthetase: Protein purification, cloning and functional expression of cDNA
16. A multienzyme complex of carbamoyl-phosphate synthase (glutamine): aspartate carbamoyltransferase: dihydroorotase (rat ascites hepatoma cells and rat liver)
17. Rapid conversion of newly-synthesized orotate to undine 5′-monophosphate by rat liver cytosolic enzymes
18. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.
19. Modified methods for the determination of carbamyl aspartate
20. Inhibitors of the de novo pyrimidine pathway
21. Orotate phosphoribosyltransferase:orotidylate decarboxylase (Ehrlich ascites cell)
22. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium
23. Purification of the primary dihydroortate dehydrogenase (oxidase) from rat liver mitochondria
24. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar sodium (NCS 368 390) in vitro